Literature DB >> 17492593

Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.

Magnus Gisslen1, Lars Hagberg, Bruce J Brew, Paola Cinque, Richard W Price, Lars Rosengren.   

Abstract

The light subunit of neurofilament protein (NFL) is a sensitive indicator of central nervous system axonal injury. We retrospectively identified 9 subjects participating in a longitudinal cohort study who developed acquired immunodeficiency syndrome dementia complex (ADC) and who had had a lumbar puncture performed within 2 years before presentation. Elevated cerebrospinal fluid (CSF) NFL concentrations were found in 7 (78%) of the 9 case patients who later developed ADC, compared with 9 (33%) of 27 CD4 cell count-matched HIV-1-infected control subjects. By contrast, no differences were found in CSF HIV-1 RNA or neopterin concentrations between the 2 groups. CSF NFL may prove to be a useful predictive marker for ADC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492593     DOI: 10.1086/518043

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

Review 1.  YKL-40: a candidate biomarker for simian immunodeficiency virus and human immunodeficiency virus encephalitis?

Authors:  Dennis L Kolson
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

2.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Authors:  Viktor Dahl; Julia Peterson; Dietmar Fuchs; Magnus Gisslen; Sarah Palmer; Richard W Price
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

3.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

4.  Diagnostic and prognostic biomarkers for HAND.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

5.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

6.  HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.

Authors:  Beau M Ances; David B Clifford
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

7.  Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.

Authors:  Lars Hagberg; Paola Cinque; Magnus Gisslen; Bruce J Brew; Serena Spudich; Arabella Bestetti; Richard W Price; Dietmar Fuchs
Journal:  AIDS Res Ther       Date:  2010-06-03       Impact factor: 2.250

8.  Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-14

9.  Lower cognitive reserve in the aging human immunodeficiency virus-infected brain.

Authors:  Linda Chang; John L Holt; Renat Yakupov; Caroline S Jiang; Thomas Ernst
Journal:  Neurobiol Aging       Date:  2012-11-15       Impact factor: 4.673

Review 10.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.